Drug Trial Radar · NCT02951156
Avelumab In Combination Regimens That Include An Immune Agonist, Epigenetic Modulator, CD20 Antagonist and/or Conventional Chemotherapy in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)
Last checked: Nov 19, 2026Latest source record: Dec 17, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
29
Actual
Start
Dec 16, 2016
Primary completion
Dec 2, 2019
Study completion Dec 2, 2019
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- Collaborators
- EMD Serono
- First posted
- Nov 1, 2016
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Study B9991011 is a multi-center, international, randomized, open label, 2 component (Phase 1b followed by Phase 3), parallel-arm study of avelumab in combination with various agents for the treatment of Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL).
Conditions
- Diffuse Large B-Cell Lymphoma
Interventions
AvelumabBiological
Investigational fully human anti-PD-L1 monoclonal antibody
UtomilumabBiological
Investigational, fully human IgG2 CD 137/4-1BB agonist
RituximabBiological
CD20-directed cytolytic antibody
AzacitidineOther
Antimetabolite antineoplastic agent and demethylation agent.
BendamustineDrug
Alkylating drug
GemcitabineDrug
Nucleoside analogue
OxaliplatinDrug
Platinum-based drug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Dose Limiting Toxicities (DLT)Time frame: Day 1 Cycle 1 up to 4 Weeks
- Objective Response Rate (ORR) as Assessed by Investigator Per Lugano Response Classification CriteriaTime frame: Randomization until date of PD, start of new anticancer therapy, discontinuation from study or death due to any cause, whichever occurred first (maximum up to 36 months)
Locations
29 sites in 8 countries. Site status is shown where the registry gives one.
City of Hope
Duarte, California
Norton Cancer Institute
Louisville, Kentucky
Norton Diagnostic Center - Dupont
Louisville, Kentucky
Norton Women's and Children's Hospital
Louisville, Kentucky
Tulane Medical Center
New Orleans, Louisiana
Parexel International
Billerica, Massachusetts
University of Michigan Health System
Ann Arbor, Michigan
Mayo Clinic
Rochester, Minnesota
North Shore Hematology Oncology Associates
East Setauket, New York
St. George Hospital
Kogarah, New South Wales, Australia
Monash Health
Clayton, Victoria, Australia
Cancer Clinical Trials Centre, Austin Health, Level 4
Heidelberg, Victoria, Australia
Genesis Care
Heidelberg, Victoria, Australia
UZ Gent
Ghent, Belgium
UZ Leuven
Leuven, Belgium
Farmacia Studi Clinici
Rozzano, MI, Italy
Istituto Clinico Humanitas
Rozzano, MI, Italy
Nzoz McD Voxel Osrodek Pet-Tk-Nmr
Krakow, Poland
Centrum Onkologii Ziemi Lubelskiej im. Sw. Jana z Dukli Oddzial Hematologiczny
Lublin, Poland
NU-MED Centrum Diagnostyki i Terapii Onkologicznej Zamosc Sp. z o.o.
Zamość, Poland
Malopolskie Centrum Medyczne S.C.
Krakow, Lesser Poland Voivodeship, Poland
Centrum Onkologii Ziemi Lubelskiej im. Sw. Jana z Dukli
Lublin, Lublin Voivodeship, Poland
Samsung Medical Center Clinical Trial Pharmacy
Seoul, South Korea
Samsung Medical Center
Seoul, South Korea
Hospital San Pedro de Alcantara
Cáceres, Spain
Centro de Investigación Medicina Especializada Sanitaria (CIMES)
Málaga, Spain
Hospital Universitario Virgen de la Victoria
Málaga, Spain
The Christie NHS Foundation Trust
Manchester, United Kingdom
The Christie Pathology Partnership
Manchester, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.